Pumvc3-Higfbp-2 Multi-Epitope Plasmid Dna Vaccine
Ovarian Carcinoma
Explore 236 assets in Ovarian Carcinoma →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
University of Washington
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07495124CT.gov IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence | — | Not Yet Recruiting | — | — | — |
NCT03029611CT.gov IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery | — | Terminated | — | — | — |
NCT01322802CT.gov Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pumvc3-Higfbp-2 Multi-Epitope Plasmid Dna Vaccine (this asset) | University of Washington | P2 | CCC · 54 |
| Mirvetuximab Soravtansine | AstraZeneca | P3 | BBB |
| Trabectedin | AGO Research GmbH | P4 | BBB |
| Olaparib | Imunon | P4 | BB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BB |
| Carboplatin | University of Washington | P3 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
| Durvalumab | AGO Research GmbH | P2 | BB |
+42 more in the Ovarian Carcinoma cohort
Other indications for Pumvc3-Higfbp-2 Multi-Epitope Plasmid Dna Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P2 | CCC · 50 |
| Fallopian Tube Cancer | — | P2 | CCC · 50 |
| Ovarian Cancer | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pumvc3-Higfbp-2 Multi-Epitope Plasmid Dna Vaccine in Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pumvc3-higfbp-2-multi-epitope-plasmid-dna-vaccine-ovarian-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →